The International Immunoglobulin Symposium
For almost three decades, CSL Behring has sponsored a high-level scientific symposium
in Interlaken, Switzerland. First held in 1981, the International Immunoglobulin
Symposium focuses exclusively on scientific and clinical research in the field of
Research presented at the Interlaken symposium is consistently at the forefront
of immunoglobulin research. Since its inception, the International Immunoglobulin
Symposium has won the respect and support of top international scientists and clinicians
from many different fields of research.
Nearly 300 scientists and clinicians attended the 6th International Immunoglobulin
Symposium, which was held in Interlaken on March 26–28, 2009. Attendees discussed
findings from a broad range of immunoglobulin research, which included investigations
into potential new indications for clinical immunoglobulin therapies, such as Guillain–Barré
syndrome, chronic inflammatory demyelinating polyneuropathy, Alzheimer’s disease
and multiple sclerosis.
About CSL Behring
CSL Behring is a global leader in the plasma protein biotherapeutics industry. We
research, develop, manufacture and market biotherapies that are used to treat serious
and rare conditions. Users of our therapies rely on them for their quality of life
and, in many cases, for life itself.
Our commitment to saving lives and improving the quality of life for people with
serious and rare conditions is evident in everything we do. Whether we are manufacturing
and marketing safe and effective products or researching and developing innovative
biotherapies, we are first and foremost focused on fulfilling our customers’ needs.
In 1981, CSL Behring’s predecessor company released Sandoglobulin®,the first non-modified
immunoglobulin concentrate marketed worldwide for intravenous infusion. Today, CSL
Behring continues to demonstrate its commitment to immunoglobulin research by sponsoring
the International Immunoglobulin Symposium and the Interlaken Leadership Awards.